证券代码：002612 证券简称：朗姿股份 公告编号：2026-006 一、本期业绩预计情况 朗姿股份有限公司（以下简称"公司"）是否需追溯调整或重述以前年度会 计数据：是 追溯调整原因：同一控制下企业合并 2025 年 9 月，公司下属全资子公司北京朗姿医疗管理有限公司以现金方式 收购重庆米兰柏羽时光整形美容医院有限公司（以下简称"重庆时光"）67.50% 股权。本次收购属于同一控制下企业合并，按照《企业会计准则》相关规定，需 对 2024 年 12 月 31 日的合并资产负债表、2024 年 1-12 月的合并利润表及合并 现金流量表相关财务数据进行追溯调整，即公司将重庆时光 2024 年 1-12 月和 2025 年 1-9 月的经营成果及现金流量纳入合并财务报表。 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况 预计净利润为正值且属于下列情形：同比上升 朗姿股份有限公司 2025年年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特此公告。 朗姿股份有限公司董事会 以区间进行业绩预告 ...

Core Viewpoint - The company, Langzi Co., Ltd., expects a significant increase in net profit for the fiscal year 2025, projecting a range of 900 million to 1.05 billion yuan, representing a year-on-year growth of 245.25% to 302.80% [1] Financial Performance - The anticipated increase in net profit is primarily attributed to the disposal of a portion of shares in Guangzhou Ruoyuchen Technology Co., Ltd. (referred to as "Ruoyuchen") and the reclassification of remaining equity in Ruoyuchen from long-term equity investment to trading financial assets, which will recognize investment income and subsequent fair value changes [1] - The impact on net profit from these activities is estimated to be approximately 725 million yuan [1]

Core Viewpoint - The company is accelerating its national layout in the medical beauty business and establishing a long-term incentive mechanism through investments in new or existing medical beauty institutions by its wholly-owned subsidiary, Langzi Medical Management Group [2] Group 1: Business Strategy - Langzi Medical Management Group is collaborating with management and key employees in the medical beauty sector to invest in new medical beauty institutions [2] - The transaction aims to enhance the motivation of key employees and improve the operational performance of the subsidiary, constituting a related party transaction [2] Group 2: Financial Performance - For the first three quarters of 2025, the company achieved total operating revenue of 4.328 billion yuan, representing a year-on-year increase of 0.89% [2] - The net profit attributable to the parent company reached 989 million yuan, showing a significant year-on-year growth of 366.95% [2] Group 3: Risk Management - The company asserts that the arrangement is controllable in terms of risk and will not have a significant adverse impact on its financial and operational status [2] - There are no circumstances that would harm the rights and interests of the listed company and minority shareholders [2] - The company will follow approval and information disclosure procedures for any future related party transactions to ensure fair pricing [2]

Group 1 - The company held its 37th meeting of the fifth board of directors on January 16, 2026, to discuss and approve a proposal regarding joint investment with related parties [2][4] - The proposal aims to accelerate the national layout strategy of the company's medical beauty business and establish a long-term incentive and restraint mechanism for key employees [3][8] - The company has been utilizing employee stock ownership platforms to jointly invest in new medical beauty institutions since July 2017, with the full subsidiary, Langzi Medical Management Group Co., Ltd., acting as the general partner [3][8] Group 2 - The board approved the proposal with a unanimous vote, with one related director abstaining from the vote [4][9] - The independent directors held a special meeting and agreed that the pricing and terms of the related transactions are fair and do not harm the interests of the company or its minority shareholders [29][30] - The expected investment amounts for key personnel involved in the employee stock ownership platforms were detailed, with specific figures provided for each individual [10][12][14][15]

Group 1 - The company Langzi Co., Ltd. announced that its 37th meeting of the fifth board of directors was held on January 16, 2026, via communication and on-site methods [1] - The meeting reviewed documents including a proposal regarding joint investment with related parties and associated transactions [1] Group 2 - The short drama industry has experienced a significant boom, creating 690,000 jobs [1] - Actors who previously worked as delivery personnel have found employment in this sector, reporting decent but exhausting income [1] - The production teams are equipped with emergency medical supplies, indicating the demanding nature of the work, especially for scenes requiring sleep [1]

上述员工持股平台为公司控制的结构化主体，纳入公司合并报表范围。公司 董事会同意公司董事、朗姿医管总经理赵衡先生，公司原监事（公司已取消监事 会）李婷女士，公司副总经理、服装板块总裁常静女士，公司总经理助理、朗姿 医管副总经理兼米兰柏羽事业部总经理朱杨柳先生和公司总经理助理、朗姿医管 副总经理兼晶肤事业部总经理李家平先生因参与上述员工持股平台构成与朗姿 医管共同投资暨关联交易事项。 证券代码：002612 证券简称：朗姿股份 公告编号：2026-004 朗姿股份有限公司 第五届董事会第三十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 朗姿股份有限公司（以下简称"公司"或"朗姿股份"）第五届董事会第三十七 次会议通知于 2026 年 1 月 13 日以电话、微信等方式发出，于 2026 年 1 月 16 日以通讯及现场会议方式召开。会议由董事长申东日先生主持，会议应出席董事 5 人，实际出席 5 人。本次会议的召开符合《中华人民共和国公司法》《公司章 程》《公司董事会议事规则》的有关规定，合法有效。 二、董事会会议审议情 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2026-005 2026 年 1 月 16 日，公司召开第五届董事会第三十七次会议，审议通过了《关 于与关联人共同投资暨关联交易的议案》，同意公司部分董事、高管及原监事（公 司已取消监事会）因参与上述员工持股平台构成的关联方共同投资暨关联交易事 项（以下简称"共同投资"）。其中，董事赵衡先生对该议案回避表决。具体情 况如下（以下货币单位"元"均指"人民币元"）： 1、截至本公告披露日，公司董事、朗姿医管总经理赵衡先生在过往十二个 月内通过以下员工持股平台投资及退出的共同投资累计发生金额 103.61 万元。 单位：万元 | 员工持股平台名称 | 参与金额 | | 退出金额 | | --- | --- | --- | --- | | 成都姿韵 | | 24.4 | 68.81 | | 成都韵甜 | | 0 | 10.4 | 一、本次交易概述 为了加快落地朗姿股份有限公司（以下简称"公司"或"朗姿股份"）医美 业务的全国布局战略，充分调动管理层和医美业务板块主要骨干员工的积极性， 建立与企业共享、共担的长效激励和约束机制，提升子公司的经营业绩，公司全 资子公 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights the competitive advantage of Qian Dama through its "community small store + daily clearance mechanism + warehouse and cold chain" model, which enhances supply stability and operational efficiency [3][24][35] - The report emphasizes the importance of emotional consumption themes and identifies high-quality companies in high-growth sectors, recommending specific companies across various segments [6][37] Summary by Sections Industry Overview - The retail and social service indices reported a decline of 1.47% and an increase of 1.53% respectively during the week of January 12-16, 2026 [5][13] - The internet e-commerce sector showed the highest growth, with a year-to-date increase of 11.18% [16][19] Company Highlights - Qian Dama has submitted its IPO application to the Hong Kong Stock Exchange, focusing on fresh food retail in the South China market, with a GMV of 9.8 billion yuan in 2024, significantly outperforming its competitors [24][25] - The company operates 2,983 stores, with 2,898 being franchise stores, contributing over 90% of its revenue [25][31] - The report recommends several companies based on their performance and market positioning, including: - Chaohongji, expected to achieve a net profit of 436-533 million yuan in 2025, driven by brand upgrades and channel expansion [39][43] - Meilitiantian Medical Health, projected to see a revenue increase of 28.2% in FY2025H1 [39] - Zhou Dafu, focusing on product structure optimization and store upgrades [39] Investment Themes - Investment Theme 1: Focus on high-end gold and fashion jewelry brands, recommending Chaohongji and Laopu Gold [6][37] - Investment Theme 2: Emphasize retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket and Aiyingshi [6][37] - Investment Theme 3: Highlight domestic beauty brands that meet emotional value and safety innovation, recommending Maogeping and Pola [6][37] - Investment Theme 4: Focus on differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending Meilitiantian Medical Health and Aimeike [6][37]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 本期债券将于2026年01月24日兑付，现将有关事宜公告如下。 一、本期债券基本情况 ■ 二、兑付相关事宜 托管在银行间市场清算所股份有限公司的债券，其兑付资金由发行人在规定时间之前划付至银行间市场 清算所股份有限公司指定的收款账户后，由银行间市场清算所股份有限公司在兑付日划付至债券持有人 指定的银行账户。债券兑付日如遇法定节假日，则划付资金的时间相应顺延。债券持有人资金汇划路径 变更，应在兑付前将新的资金汇划路径及时通知银行间市场清算所股份有限公司。因债券持有人资金汇 划路径变更未及时通知银行间市场清算所股份有限公司而不能及时收到资金的，发行人及银行间市场清 算所股份有限公司不承担由此产生的任何损失。 三、相关机构联系人和联系方式 （一）发行人：朗姿股份 联系人：蒋琼 朗姿股份有限公司（以下简称"朗姿股份"或"公司"）第四届董事会第三十一次会议和2022年第二次临时 股东大会分别审议通过了《关于拟申请注册发行中期票据的议案》，同意公司向中国银行间市场交易商 协会 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2026-003 本期债券将于 2026 年 01 月 24 日兑付，现将有关事宜公告如下。 | 发行人名称 | 朗姿股份 | | --- | --- | | 债项名称 | 朗姿股份有限公司 2024 年度第一期中期票据 | | 债项简称 | 24 朗姿 MTN001 | | 债项代码 | 102400592 | | 发行金额 | 2.20 亿元 | | 起息日 | 2024 年 01 月 24 日 | | 发行期限 | 2 年 | | 债项余额 | 2.20 亿元 | 一、本期债券基本情况 | 偿还类别 | 本息兑付 | | --- | --- | | 本计息期债项利率 | 2.98% | | 本息兑付日 | 2026 年 01 月 24 日（若遇法定节假日，支付日顺延 | | | 至法定节假日后第一个工作日） | | 本期应偿付本息金额 | 2.27 亿元 | | 主承销商 | 浙商银行股份有限公司 | | | 中信证券股份有限公司 | | 存续期管理机构 | 浙商银行股份有限公司 | | 登记托管机构 | 银行间市场清算所股份有限公司 | 朗姿股份有 ...